Notably, elective terminations were higher (18%) in the GLP-1 group, driven largely by patient anxiety rather than medical necessity
Patients should maintain a symptom diary documenting any vision changes, including when they occur, their duration, severity, and any associated symptoms
Mounjaros NCPE reimbursement review, expected in 2026, may change the picture, it is considered a stronger candidate than Wegovy, given greater efficacy and a different active ingredient to Ozempic
If you are using BPC-157 to settle a gut issue or support tissue repair, heavy drinking keeps reintroducing the stress you are working to resolve
By comparison, Mounjaros pivotal SURMOUNT-1 trial reported up to around 22.5% mean weight loss at 72 weeks, and Wegovys STEP-1 trial reported around 14.9% at 68 weeks
Dowling LR, Strazzari MR, Keely S, Kaiko GE